Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease
Open accessThe DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is a major worldwide health problem. Recent studies suggest that the gut microbiota influences NAFLD pathogenesis. Here, a murine model of high-fat diet-induced (HFD-induced) NAFLD was used, and the effects of alterations in the gut microbiota on NAFLD were determined. Mice treated with antibiotics or tempol exhibited altered bile acid composition, with a notable increase in conjugated bile acid metabolites that inhibited intestinal farnesoid X receptor (FXR) signaling. Compared with control mice, animals with intestine-specific Fxr disruption had reduced hepatic triglyceride accumulation in response to a HFD. The decrease in hepatic triglyceride accumulation was mainly due to fewer circulating ceramides, which was in part the result of lower expression of ceramide synthesis genes. The reduction of ceramide levels in the ileum and serum in tempol- or antibiotic-treated mice fed a HFD resulted in downregulation of hepatic SREBP1C and decreased de novo lipogenesis. Administration of C16:0 ceramide to antibiotic-treated mice fed a HFD reversed hepatic steatosis. These studies demonstrate that inhibition of an intestinal FXR/ceramide axis mediates gut microbiota-associated NAFLD development, linking the microbiome, nuclear receptor signaling, and NAFLD. This work suggests that inhibition of intestinal FXR is a potential therapeutic target for NAFLD treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Hence, treatment with antibiotics ameliorates high-fat-diet-induced NAFLD in mice55.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [55]
In the citing paper
“Conversely, some data also indicate that antagonism of intestinal FXR signaling could improve metabolic parameters in murine models of NAFLD [256,257].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [257]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An obesity-associated gut microbiome with increased capacity for energy harvest
Turnbaugh, P. J., Ley, R. E., Mahowald, M. A., Magrini, V., Mardis, E. R., & Gordon, J. I. (2006) · Nature · doi:10.1038/nature05414 · Cited by 12,444
The gut microbiota as an environmental factor that regulates fat storage
Bäckhed, F., Ding, H., Wang, T., Hooper, L. V., Koh, G. Y., Nagy, A., Semenkovich, C. F., & Gordon, J. I. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407076101 · Cited by 6,245
Functional interactions between the gut microbiota and host metabolism
Tremaroli, V., & Bäckhed, F. (2012) · Nature · doi:10.1038/nature11552 · Cited by 4,387
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604
Bile salt biotransformations by human intestinal bacteria
Ridlon, J. M., Kang, D.-J., & Hylemon, P. B. (2006) · Journal of Lipid Research · doi:10.1194/jlr.r500013-jlr200 · Cited by 2,829
Mechanisms underlying the resistance to diet-induced obesity in germ-free mice
Bäckhed, F., Manchester, J. K., Semenkovich, C. F., & Gordon, J. I. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605374104 · Cited by 2,615
Sayin, S. I., Wahlström, A., Felin, J., Jäntti, S., Marschall, H.-U., Bamberg, K., Angelin, B., Hyötyläinen, T., Orešič, M., & Bäckhed, F. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.01.003 · Cited by 2,331
Human gut microbiota in obesity and after gastric bypass
Zhang, H., DiBaise, J. K., Zuccolo, A., Kudrna, D., Braidotti, M., Yu, Y., Parameswaran, P., Crowell, M. D., Wing, R., Rittmann, B. E., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812600106 · Cited by 1,880
Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis
Inagaki, T., Choi, M., Moschetta, A., Peng, L., Cummins, C. L., McDonald, J. G., Luo, G., Jones, S. A., Goodwin, B., Richardson, J. A., et al. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.09.001 · Cited by 1,865
Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis
Sinal, C. J., Tohkin, M., Miyata, M., Ward, J. M., Lambert, G., & Gonzalez, F. J. (2000) · Cell · doi:10.1016/s0092-8674(00)00062-3 · Cited by 1,819 · cited 1×
“FXR, the central sensor and regulator for the biosynthesis and enterohepatic recycling of bile acids, plays a pivotal role in the control of lipid metabolism (42–45).”
Self-citation
Research works printed but not linked: 1
- 10.1172/jci21025 · DOI · Paper page
Cited by
Items 301–400 of 746
Wang, W., Zhang, Y., Wang, Z., Zhang, J., & Jia, L. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.116321 · Cited by 44
Luo, X., Wang, K., & Jiang, C. (2025) · Cell Host & Microbe · doi:10.1016/j.chom.2025.04.020 · Cited by 45
Self-citationMicrobiota-derived bile acid metabolic enzymes and their impacts on host health
Ma, H., Wang, K., & Jiang, C. (2025) · Cell Insight · doi:10.1016/j.cellin.2025.100265 · Cited by 46
Self-citationBile acid homeostasis in gastrointestinal and metabolic complications of cystic fibrosis
van de Peppel, I. P., Bodewes, F. A. J. A., Verkade, H. J., & Jonker, J. W. (2018) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2018.08.009 · Cited by 45
Xiong, F., Zheng, Z., Xiao, L., Su, C., Chen, J., Gu, X., Tang, J., Zhao, Y., Luo, H., & Zha, L. (2021) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202100067 · Cited by 44
Sergi, D., Zauli, E., Celeghini, C., Previati, M., & Zauli, G. (2024) · Nutrition Research Reviews · doi:10.1017/s0954422424000179 · Cited by 44
Ceramides: Nutrient Signals that Drive Hepatosteatosis
Summers, S. A. (2020) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2020.9.1.50 · Cited by 43
Zhao, L., Ma, P., Peng, Y., Wang, M., Peng, C., Zhang, Y., & Li, X. (2021) · Phytomedicine · doi:10.1016/j.phymed.2021.153477 · Cited by 44
Zhou, W., & Anakk, S. (2022) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2022.111616 · Cited by 43
Zhang, C., Liu, Y., Wang, Y., Ge, X., Jiao, T., Yin, J., Wang, K., Li, C., Guo, S., Xie, X., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01394 · Cited by 43
Self-citationKobyliak, N. M., Falalyeyeva, T. M., Virchenko, O., Mykhalchyshyn, G., Bodnar, P., NIa, S., Yankovsky, D., Beregova, T. V., & Остапченко, Л. І. (2016) · BMC Gastroenterology · doi:10.1186/s12876-016-0451-2 · Cited by 42
Rethinking Bile Acid Metabolism and Signaling for Type 2 Diabetes Treatment
Zaborska, K. E., & Cummings, B. P. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1092-3 · Cited by 43
Tveter, K. M., Villa-Rodríguez, J. A., Cabales, A., Zhang, L., Bawagan, F. G., Duran, R. M., & Roopchand, D. E. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001386 · Cited by 42
Self-citationXie, Z., Jiang, H., Liu, W., Zhang, X., Chen, D., Sun, S.-M., Zhou, C., Liu, J., Bao, S., Wang, X., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02974-0 · Cited by 42
Barretto, S. A., Lasserre, F., Huillet, M., Régnier, M., Polizzi, A., Lippi, Y., Fougerat, A., Person, E., Bruel, S., Bétoulières, C., et al. (2021) · Microbiome · doi:10.1186/s40168-021-01050-9 · Cited by 42
Tang, Y., Fan, Y., Wang, Y., Wang, D., Huang, Q., Chen, T., Cao, X., Wen, C., Shen, X., Li, J., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116658 · Cited by 41
Gut microbiota therapy in gastrointestinal diseases
Ullah, H., Arbab, S., Chang, C., Bibi, S., Muhammad, N., Rehman, S. U., Suleman, S., Ullah, I., Hassan, I. U., Tian, Y., et al. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1514636 · Cited by 42
Mechanisms of nonalcoholic fatty liver disease and implications for surgery
Kaufmann, B. K., Reca, A., Wang, B., Friess, H., Feldstein, A. E., & Hartmann, D. (2020) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-020-01965-1 · Cited by 41
The intestinal microbiota as a therapeutic target in the treatment of NAFLD and ALD
Huang, W., & Kong, D. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111235 · Cited by 41
Contribution of the microbiome for better phenotyping of people living with obesity
Ciaula, A. D., Bonfrate, L., Khalil, M., Garruti, G., & Portincasa, P. (2023) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-023-09798-1 · Cited by 43
Pathophysiology of Nonalcoholic Fatty Liver Disease: Lifestyle-Gut-Gene Interaction
Mazzotti, A., Caletti, M. T., Sasdelli, A. S., Brodosi, L., & Marchesini, G. (2016) · Digestive Diseases · doi:10.1159/000447275 · Cited by 41
Fang, Z., Tanaka, N., Lü, D., Jiang, C., Zhang, W.-H., Zhang, C., Du, Z., Fu, Z., Gao, P., Cao, Y., et al. (2016) · Archives of Toxicology · doi:10.1007/s00204-016-1877-6 · Cited by 41
Self-citationAmerican Diabetes Association and JDRF Research Symposium: Diabetes and the Microbiome
Semenkovich, C. F., Danska, J. S., Darsow, T., Dunne, J. L., Huttenhower, C., Insel, R. A., McElvaine, A. T., Ratner, R. E., Shuldiner, A. R., & Blaser, M. J. (2015) · Diabetes · doi:10.2337/db15-0597 · Cited by 40
Halilbasic, E., Fuchs, C., Traussnigg, S., & Trauner, M. (2016) · Digestive Diseases · doi:10.1159/000445268 · Cited by 39
FXR and NASH: an avenue for tissue-specific regulation
Henry, Z. R., Meadows, V., & Guo, G. L. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000127 · Cited by 40
Xenobiotic Receptor-Mediated Regulation of Intestinal Barrier Function and Innate Immunity
Ranhotra, H. S., Flannigan, K. L., Brave, M., Mukherjee, S., Lukin, D. J., Hirota, S. A., & Mani, S. (2016) · Nuclear Receptor Research · doi:10.11131/2016/101199 · Cited by 39
Milton‐Laskibar, I., Marcos-Zambrano, L. J., Gómez‐Zorita, S., Fernández‐Quintela, A., Pau, E. C. D. S., Martínez, J. A., & Portillo, M. P. (2021) · Nutrients · doi:10.3390/nu13051738 · Cited by 38
Zhao, Y., He, Z., Hao, W., Zhu, H., Liu, J., Ma, K. Y., He, W., & Chen, Z. (2021) · Food & Function · doi:10.1039/d1fo02906a · Cited by 38
Li, X., Suo, J., Huang, X., Dai, H.-F., Bian, H., Zhu, M., Lin, W., & Han, N. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.761727 · Cited by 38
Nonalcoholic fatty liver disease shows significant sex dimorphism
Chen, X., Wang, C., Huang, Y., & Zhang, L. (2022) · World Journal of Clinical Cases · doi:10.12998/wjcc.v10.i5.1457 · Cited by 40
Self-citationBile acids and salt-sensitive hypertension: a role of the gut-liver axis
Ishimwe, J., Dola, T., Ertuğlu, L. A., & Kirabo, A. (2022) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00027.2022 · Cited by 38
Carino, A., Marchianò, S., Biagioli, M., Fiorucci, C., Zampella, A., Monti, M. C., Morretta, E., Bordoni, M., Giorgio, C. D., Roselli, R., et al. (2019) · Nutrients · doi:10.3390/nu11051132 · Cited by 38
Withaferin A Improves Nonalcoholic Steatohepatitis in Mice
Patel, D. P., Yan, T., Kim, D., Dias, H. B., Krausz, K. W., Kimura, S., & Gonzalez, F. J. (2019) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.256792 · Cited by 38
Self-citationBile acid treatment and FXR agonism lower postprandial lipemia in mice
Farr, S., Stankovic, B., HOFFMAN, S. S., Masoudpoor, H., Baker, C., Taher, J., Dean, A. E., Anakk, S., & Adeli, K. (2020) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00386.2018 · Cited by 38
Targeted inhibition of hepatic de novo ceramide synthesis ameliorates MASH
Yu, X., Huang, C., Evers, M. J. W., Liu, J., Ting, H. J., Zhang, S., Chong, S. Y., Tan, M. S., Wang, S., Sayed, N., et al. (2025) · Science Advances · doi:10.1126/sciadv.adx2681 · Cited by 37
Zhang, N., Tao, J., Gao, L., Bi, Y., Li, P., Wang, H., Zhu, D., & Feng, W. (2020) · BioMed Research International · doi:10.1155/2020/2947549 · Cited by 31
Molina, L. M., Zhu, J., Qin, L., Pradhan‐Sundd, T., Krutsenko, Y., Sayed, K., Jenkins, N. E. C., Vats, R., Bhushan, B., Ko, S., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109310 · Cited by 37
Zhang, L., Hu, Y., An, Y., Wang, Q., Liu, J., & Wang, G. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.677202 · Cited by 38
Self-citationSteroidal Scaffolds as FXR and GPBAR1 Ligands: From Chemistry to Therapeutical Application
Sepe, V., Distrutti, E., Limongelli, V., Fiorucci, S., & Zampella, A. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.54 · Cited by 37
McGettigan, B. M., McMahan, R. H., Luo, Y., Wang, X. X., Orlicky, D. J., Porsche, C., Levi, M., & Rosen, H. R. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.731042 · Cited by 35
Enteric Microbiota–Gut–Brain Axis from the Perspective of Nuclear Receptors
Duszka, K., & Wahli, W. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082210 · Cited by 39
The delayed effects of antibiotics in type 2 diabetes, friend or foe?
Fu, L., Qiu, Y., Shen, L., Cui, C., Wang, S., Wang, S., Xie, Y., Zhao, X., Gao, X., Ning, G., et al. (2018) · Journal of Endocrinology · doi:10.1530/joe-17-0709 · Cited by 36
Paraiso, I. L., Revel, J. S., Choi, J., Miranda, C. L., Lak, P., Kioussi, C., Bobe, G., Gombart, A. F., Raber, J., Maier, C. S., et al. (2020) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202000341 · Cited by 36
Yang, C., Wan, M., Xu, D., Pan, D., Xia, H., Yang, L., & Sun, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910858 · Cited by 37
Gut microbiota, immunity, and bile acid metabolism: decoding metabolic disease interactions
Zhao, Q., Wu, J., Ding, Y., Pang, Y., & Jiang, C. (2023) · Life Metabolism · doi:10.1093/lifemeta/load032 · Cited by 35
Self-citationGao, Y., Lin, J., Ye, C., Guo, S., & Jiang, C. (2023) · Liver Research · doi:10.1016/j.livres.2023.09.002 · Cited by 36
Self-citationDai, J.-J., Zhang, Y., & Zhang, Z. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i37.5339 · Cited by 37
Patankar, J. V., Wong, C. K., Morampudi, V., Gibson, W. T., Vallance, B. A., Ioannou, G. N., & Hayden, M. R. (2017) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00172.2017 · Cited by 35
Zhao, Y., Xu, H., Tian, Z., Wang, X., Xu, L., Li, K., Gao, X., Fan, D., Ma, X., Ling, W., et al. (2020) · Clinical Nutrition · doi:10.1016/j.clnu.2020.10.014 · Cited by 35
Sciarrillo, C. M., Keirns, B. H., Koemel, N. A., Anderson, K. L., & Emerson, S. R. (2021) · Liver International · doi:10.1111/liv.14802 · Cited by 35
The Role of the Microbiome in Liver Cancer
Moreno‐Gonzalez, M., & Beraza, N. (2021) · Cancers · doi:10.3390/cancers13102330 · Cited by 35
Linking Nonalcoholic Fatty Liver Disease and Brain Disease: Focusing on Bile Acid Signaling
Ren, Z., Li, C.-X., Ma, C., Chen, D., Chen, J., Xu, W., Chen, C.-A., Cheng, F., & Wang, X. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113045 · Cited by 34
Gut microbiota in MAFLD: therapeutic and diagnostic implications
Alghamdi, W., Mosli, M. H., & Alqahtani, S. A. (2024) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188241242937 · Cited by 34
Liu, Q., Yang, M., Fu, X., Liu, R., Sun, C., Pan, H., Wong, C., & Guan, M. (2016) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2016.07.027 · Cited by 34
Tian, J., Jin, Y.-Q., Yu, E., Sun, J., Xia, Y. L., Zhang, K., Li, Z., Gong, W., Wang, G.-J., & Xie, J. (2020) · Aquaculture · doi:10.1016/j.aquaculture.2020.736248 · Cited by 34
Pathogenesis of NASH and Promising Natural Products
Leng, Y., Zhang, M., Luo, J., & Zhang, H. (2021) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(21)60002-x · Cited by 34
Xue, M., Liang, H., Zhou, Z., Liu, Y., He, X., Zhang, Z., Sun, T., Yang, J., Qin, Y., & Qin, K. (2021) · Food & Nutrition Research · doi:10.29219/fnr.v65.5384 · Cited by 34
Beau, A., Benoit, B., Barz, M. L., Meugnier, E., Penhoat, A., Calzada, C., Pinteur, C., Loizon, E., Chanon, S., Vieille‐Marchiset, A., et al. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2281015 · Cited by 34
Vauzour, D., Rodríguez‐Ramiro, I., Rushbrook, S., Ipharraguerre, I. R., Bevan, D., Davies, S. E., Tejera, N., Mena, P. R., de Pascual‐Teresa, S., Rio, D. D., et al. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.10.002 · Cited by 34
Targeting bile acids and lipotoxicity for NASH treatment
Chiang, J. Y. L. (2017) · Hepatology Communications · doi:10.1002/hep4.1127 · Cited by 32
Luo, Z., Zhou, W., Xie, T., Xu, W., Shi, C., Xiao, Z., Si, Y., Ma, Y., Ren, Q., Di, L., et al. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.04.027 · Cited by 33
Wang, Y., Yu, J., Chen, B., Jin, W., Wang, M., Chen, X., Jian, M., Sun, L., & Piao, C. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1481270 · Cited by 33
Zhang, X., Li, H., Li, Y., Jiang, G., Ji, C., Zhang, Q., & Zhao, F. (2021) · Journal of Food Composition and Analysis · doi:10.1016/j.jfca.2021.103988 · Cited by 33
Potential of Intestine-Selective FXR Modulation for Treatment of Metabolic Disease
van Zutphen, T., Bertolini, A., de Vries, H. D., Bloks, V. W., de Boer, J. F., Jonker, J. W., & Kuipers, F. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_233 · Cited by 33
Ramos‐Molina, B., Rossell, J., de, A. P.-M., Pardina, E., Genua, I., Rojo-López, M. I., Julián, M. T., Alonso, N., Julve, J., & Mauricio, D. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1400961 · Cited by 33
Chu, H., Jiang, L., Gao, B., Gautam, N., Alamoudi, J. A., Lang, S., Wang, Y., Duan, Y., Alnouti, Y., Cable, E. E., et al. (2020) · Translational research · doi:10.1016/j.trsl.2020.06.006 · Cited by 32
Wang, X., Jin, Y., Di, C., Zeng, Y., Zhou, Y., Chen, Y., Pan, Z., Li, Z., & Ling, W. (2024) · Nutrients · doi:10.3390/nu16081169 · Cited by 32
l-Fucose ameliorates high-fat diet-induced obesity and hepatic steatosis in mice
Wu, G., Niu, M., Tang, W., Hu, J., Wei, G., He, Z., Chen, Y., Jiang, Y., & Chen, P. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1718-x · Cited by 32
Microbiota-Associated Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Cancer: A Review
Chen, Y., Wu, W., & Wu, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21175999 · Cited by 32
Recent insights into the pathogenesis and therapeutic targets of chronic liver diseases
Wen, Y., Ma, L., & Ju, C. (2023) · eGastroenterology · doi:10.1136/egastro-2023-100020 · Cited by 31
Zhang, K.-X., Zhu, Y., Song, S., Bu, Q.-Y., You, X., Zou, H., & Zhao, G. (2024) · Molecules · doi:10.3390/molecules29051108 · Cited by 31
Dai, Q., Ain, Q., Seth, N., Rooney, M., & Zipprich, A. (2025) · Digestive and Liver Disease · doi:10.1016/j.dld.2025.01.189 · Cited by 32
Li, Y., Hou, H., Wang, X., Dai, X., Zhang, W., Tang, Q., Dong, Y., Yan, C., Wang, B., Li, Z., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.796590 · Cited by 32
Yao, N., Yang, Y., Li, X., Wang, Y., Guo, R., Wang, X., Li, J., Xie, Z., Li, B., & Cui, W. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.906511 · Cited by 31
Inhibition of farnesoid X receptor signaling shows beneficial effects in human obesity
Gonzalez, F. J., Jiang, C., Bisson, W. H., & Patterson, A. D. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.043 · Cited by 32
Self-citationAntioxidant Drug Tempol Promotes Functional Metabolic Changes in the Gut Microbiota
Cai, J., Zhang, L., Jones, R. A., Correll, J. B., Hatzakis, E., Smith, P. B. W., Gonzalez, F. J., & Patterson, A. D. (2016) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5b00957 · Cited by 31
Self-citationFeng, L., Zhang, Y., Liu, W., Du, D., Jiang, W., Wang, Z., Li, N., & Hu, Z. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.03312-23 · Cited by 30
Grattagliano, I., Ciaula, A. D., Baj, J., Molina‐Molina, E., Shanmugam, H., Garruti, G., Wang, D. Q. ‐., & Portincasa, P. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1433-4_12 · Cited by 30
Significance of gut microbiota in alcoholic and non-alcoholic fatty liver diseases
Sharma, S. P., Suk, K. T., & Kim, D. J. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i37.6161 · Cited by 30
Nuclear receptors: a bridge linking the gut microbiome and the host
Wang, Z., Chen, W., & Wang, Y. (2021) · Molecular Medicine · doi:10.1186/s10020-021-00407-y · Cited by 30
Cui, Y., Yin, Y., Li, S., Wu, Z., Xie, Y., Qian, Q., Yang, H., & Li, X. (2022) · Food & Function · doi:10.1039/d1fo04116a · Cited by 30
Dihydroartemisinin promoted FXR expression independent of YAP1 in hepatocellular carcinoma
Guo, Y., Peng, Q., Hao, L., Ji, J., Zhang, Z., Xue, Y., Liu, Y., Gao, Y., Li, C., & Shi, X. (2022) · The FASEB Journal · doi:10.1096/fj.202200171r · Cited by 30
Yan, M., Hou, L., Cai, Y., Wang, H., Ma, Y., Geng, Q., Jiang, W., & Tang, W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.906452 · Cited by 30
Role of gut microbial metabolites in nonalcoholic fatty liver disease
Zhao, Z. H., Lai, J. K., Qiao, L., & Fan, J. (2019) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12709 · Cited by 30
Bile acid signaling in renal water regulation
Li, S., Li, C., & Wang, W. (2019) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00563.2018 · Cited by 30
Hepatic Reduction in Cholesterol 25-Hydroxylase Aggravates Diet-induced Steatosis
Dong, Z., He, F., Yan, X., Xing, Y., Lei, Y., Gao, J., He, M., Li, D., Bai, L., Yuan, Z., et al. (2022) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.12.018 · Cited by 30
Zhang, Q., Tian, F., Zhao, J., Zhang, H., Zhai, Q., & Chen, W. (2019) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2019.12.013 · Cited by 29
The Lard Works in Mysterious Ways: Ceramides in Nutrition-Linked Chronic Disease
Nicholson, R. J., Norris, M. K., Poss, A. M., Holland, W. L., & Summers, S. A. (2022) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-062220-112920 · Cited by 29
Jiang, J., Ma, Y., Liu, Y., Lu, D., Gao, X., Krausz, K. W., Desai, D. H., Amin, S., Patterson, A. D., Gonzalez, F. J., et al. (2022) · Hepatology Communications · doi:10.1002/hep4.2099 · Cited by 29
Self-citationLin, S., Wang, T., Xu, H., Zhang, X.-N., Wang, Q., Liu, R., Li, Q., & Kai-shun, B. (2019) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2019.04.009 · Cited by 29
Xu, J., Wang, R., You, S., Zhang, L., Zheng, P., Ji, G., & Liu, B. (2020) · Trials · doi:10.1186/s13063-020-04362-7 · Cited by 29
Self-citationSaeb, A., Grundmann, S. M., Geßner, D. K., Schuchardt, S., Most, E., Wen, G., Eder, K., & Ringseis, R. (2022) · Food & Function · doi:10.1039/d1fo03920b · Cited by 29
Pan, T. J., Li, X., Guo, X., Wang, H., Zhou, X., Shang, R., Xie, D., Qian, X., Dai, M., Fan, E., et al. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s421134 · Cited by 28
Yang, C.-W., Liu, H.-M., Chang, Z., Liu, G.-H., Chang, H., Huang, P., & Lee, T.-Y. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105274 · Cited by 28
Wang, P., Sun, J., Zhao, W., Wang, D., Ma, Y., Zhao, Y., Wang, Y., & Zhao, X. (2024) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.4c01598 · Cited by 28
Васильевна, Б. А., Mayorov, A. Y., Mishina, E. Е., Schwartz, A. M., & Belousov, P. V. (2018) · Diabetes Mellitus · doi:10.14341/dm9374 · Cited by 27
Gallo, G., Nalli, G., Baratta, F., Desideri, G., & Savoia, C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26168081 · Cited by 27
Das, B. K. (2022) · Apmis · doi:10.1111/apm.13282 · Cited by 27
Role of intestinal flora in primary sclerosing cholangitis and its potential therapeutic value
Li, Z.-J., Gou, H.-Z., Zhang, Y., Song, X., & Zhang, L. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i44.6213 · Cited by 27
Self-citationFeng, J., Ma, H., Yue, Y., Wang, L., Hao, K., Zhang, Y., Li, J., Xiang, Y., & Min, Y. (2023) · Poultry Science · doi:10.1016/j.psj.2023.103155 · Cited by 27
Metadata
- Authors
- Jiang, C., Xie, C., Li, F., Zhang, L., Nichols, R. G., Krausz, K. W., Cai, J., Qi, Y., Fang, Z.-Z., Takahashi, S., Tanaka, N., Desai, D., Amin, S. G., Albert, I., Patterson, A. D., & Gonzalez, F. J.
- Affiliations
- National Institutes of Health (US)
- Pennsylvania State University (US)
- Corresponding author
- Patterson, Andrew D.
- Gonzalez, Frank J.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2014-12-15
- Volume
- 125
- Issue
- 1
- Pages
- 386-402
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC4382255
- OpenAlex
- W2124025733
- Cited by
- 693
- References
- 68
- Citations by year
- 2026: 43 · 2025: 52 · 2024: 52 · 2023: 61 · 2022: 76 · 2021: 84 · 2020: 70 · 2019: 63 · 2018: 58 · 2017: 61 · 2016: 46 · 2015: 26
- FWCI
- 33.50
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute of Environmental Health Sciences (R01ES022186, ES022186)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- non-alcoholic fatty liver disease, gut microbiota, bile acids, bile acid conjugates, ceramide, ceramide synthesis, SREBP-1c, de novo lipogenesis, hepatic steatosis, high-fat diet, antibiotic therapy, tempol, nuclear receptor signaling, therapeutic target
- MeSH terms
- Receptor, Farnesoid X-Activated, Animals, Anti-Bacterial Agents, Bile Acids and Salts, Cecum, Gene Expression Regulation, Humans, Ileum, Liver, Male, Mice, Inbred C57BL, Mice, Transgenic, Gene Expression, Receptors, Cytoplasmic and Nuclear, Lipid Metabolism, Metabolic Networks and Pathways, Diet, High-Fat, Mitochondrial Dynamics, Microbiota, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.